Omnicell, Inc. OMCL has witnessed strong momentum in the past year. Shares of the company have risen 41.6% against a 11.3% decline of the industry during the same time frame. The S&P 500 composite ...

Among others, following stocks were impacted: Healthcare Technology for Providers company Omnicell (NASDAQ:OMCL) fell 5.4%. Is now the time to buy Omnicell? Access our full analysis report here ...

What a brutal six months it’s been for Omnicell. The stock has dropped 24.6% and now trades at $32.45, rattling many shareholders. This was partly driven by its softer quarterly results and may ...

Omnicell OMCL underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light ...

Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. The Boston biotech is shrinking its workforce by "approximately" 20% ...

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and ...